2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.11 (Poster) Real-world Treatment Patterns and Outcomes Among Unresectable Stage III Non-Small Cell Lung Cancer

PP01.11 (Poster) Real-world Treatment Patterns and Outcomes Among Unresectable Stage III Non-Small Cell Lung Cancer

Pdf Summary

This retrospective cohort study examined treatment utilization and outcomes for patients with unresectable stage III non-small cell lung cancer (NSCLC) who initiated concurrent chemoradiotherapy (cCRT) with or without the immune checkpoint inhibitor durvalumab. The study analyzed data from the US Oncology Network clinics that utilize the iKnowMed electronic health record system.<br /><br />A total of 426 patients were included in the final analysis, with 262 patients receiving cCRT plus durvalumab (cCRTdurvalumab) and 164 patients receiving cCRT alone. The most common chemotherapy regimen for cCRT was carboplatin plus paclitaxel.<br /><br />The study found that death and disease progression were the most common reasons for not initiating durvalumab in the cCRT alone cohort. Among the cCRTdurvalumab cohort, 51.5% discontinued durvalumab before the end of the study, primarily due to adverse events and disease progression.<br /><br />The median real-world overall survival (rwOS) from the index date was 50.2 months for the cCRTdurvalumab cohort and 11.6 months for the cCRT alone cohort. The 6-month, 12-month, 18-month, and 24-month rwOS rates were higher in the cCRTdurvalumab cohort compared to the cCRT alone cohort.<br /><br />The findings of this study highlight the treatment utilization patterns and real-world clinical outcomes for patients with unresectable stage III NSCLC after the introduction of immune checkpoint inhibitors. The results suggest that a significant proportion of patients do not receive consolidation durvalumab, mainly due to death or disease progression after initiating cCRT. These findings underscore the need for more effective treatment options for this patient population.

Asset Subtitle

A. Arunachalam

Keywords

retrospective cohort study

treatment utilization

outcomes

unresectable stage III non-small cell lung cancer

concurrent chemoradiotherapy

immune checkpoint inhibitor

durvalumab

real-world overall survival

adverse events

treatment options